دورية أكاديمية
Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
| العنوان: | Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers |
|---|---|
| المؤلفون: | Patricia Sacco, Kelley Myers, Christine Poulos, Carolyn Sweeney, Kelly Hollis, Vincenza Snow, Jeffrey T. Vietri |
| المصدر: | Infectious Diseases and Therapy, Vol 8, Iss 4, Pp 657-670 (2019) |
| بيانات النشر: | Adis, Springer Healthcare, 2019. |
| سنة النشر: | 2019 |
| المجموعة: | LCC:Infectious and parasitic diseases |
| مصطلحات موضوعية: | Adult, Health care provider, Pneumococcal vaccine, Preferences, Infectious and parasitic diseases, RC109-216 |
| الوصف: | Abstract Introduction In 2014, the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) recommended 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged ≥ 65 years, with a commitment to revisit the recommendation for PCV13 because of declining vaccine-type disease. The Evidence-to-Recommendation framework used by the ACIP includes review of evidence regarding feasibility and stakeholder acceptability, but no surveys of vaccinator preferences have been published in the literature. Methods Physicians (N = 700), physician assistants (N = 100), pharmacists (N = 100), and nurse practitioners (N = 100) who recently prescribed, administered, or recommended adult pneumococcal vaccine were surveyed in March 2018. Object-case best–worst scaling was used to assess preferences among potential recommendation scenarios: retaining the then-current 2014 recommendation without a scheduled re-evaluation, retaining with a scheduled re-evaluation, revising PCV13 to Category B (retaining PPSV23 as Category A), removing PCV13 (retaining PPSV23 as Category A), and removing both PCV13 and PPSV23. Results Providers’ most preferred recommendations were retaining the 2014 recommendation with another planned re-evaluation (52.6%) and retaining the then-current recommendation without planned re-evaluation (40.0%). Few preferred changing PCV13 to Category B (3.2%), removing PCV13 (3.7%), or removing both pneumococcal vaccines (0.5%). Conclusions The majority of vaccinators surveyed preferred to retain the 2014 recommendation, either with another scheduled reassessment or indefinitely. Funding Pfizer, Inc. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8229 2193-6382 |
| Relation: | http://link.springer.com/article/10.1007/s40121-019-00266-5; https://doaj.org/toc/2193-8229; https://doaj.org/toc/2193-6382 |
| DOI: | 10.1007/s40121-019-00266-5 |
| URL الوصول: | https://doaj.org/article/4a62e87914cc46a4a038a418f8e046c3 |
| رقم الأكسشن: | edsdoj.4a62e87914cc46a4a038a418f8e046c3 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 21938229 21936382 |
|---|---|
| DOI: | 10.1007/s40121-019-00266-5 |